|本期目录/Table of Contents|

18F-FDG PET/CT代谢的可重复性研究进展

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2019年20期
页码:
3709-3712
栏目:
综述
出版日期:
2019-09-08

文章信息/Info

Title:
Advances in repeatability of 18F-FDG PET/CT metabolism
作者:
冯 雪;?孙莹莹;?孙夕林
哈尔滨医科大学附属第四医院分子影像研究中心,黑龙江 哈尔滨 150001
Author(s):
Feng Xue;?Sun Yingying;?Sun Xilin
Molecular Imaging Research Center,the Forth Affiliated Hospital,Harbin Medical University,Heilongjiang Harbin 150001,China.
关键词:
18F-FDG PET/CT;?重复性;?代谢参数;?纹理分析;?疗效评价;?恶性肿瘤
Keywords:
18F-FDG PET/CT;?repeatability;?metabolic parameters;?texture analysis;?therapeutic evaluation;?malignant tumor
分类号:
R730
DOI:
10.3969/j.issn.1672-4992.2019.20.037
文献标识码:
A
qq自动领红包软件:
18F-脱氧葡萄糖(18F-FDG)PET/CT在恶性肿瘤的早期诊断、临床分期、疗效评价、监测复发及肿瘤放疗靶区定位中具有重要价值。为了使PET/CT能够更准确地进行恶性肿瘤的疗效评价,18F-FDG PET/CT代谢的可重复性研究显得尤为重要。本文就传统临床代谢参数值标准化摄取值(SUV)、代谢活性肿瘤体积(MATV)、总病灶糖酵解(TLG)、肿瘤与肝脏比率(TLR)、肿瘤与血液比率(SUR)及近年新兴的PET图像纹理分析等方面的可重复性研究进行概述。
Abstract:
18F-deoxyglucose (18F-FDG) PET/CT is of great value in the early diagnosis,clinical staging,efficacy evaluation,monitoring recurrence and tumor radiotherapy target location of malignant tumors.In order to enable PET/CT to more accurately evaluate the efficacy of malignant tumors,18F-FDG PET/CT metabolic parameter reproducibility studies are particularly important.In this paper,the repeatability of traditional clinical metabolic parameter values such as standardized uptake value (SUV),metabolic active tumor volume (MATV),total lesion glycolysis (TLG),tumor-liver ratio (TLR),tumor-to-blood standard uptake ratio (SUR) and texture analysis of PET images in recent years are summarized.

参考文献/References

[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].A Cancer J Clin,2015,65(2):87-108.
[2]DENG Yanyun,TENG Caijun,WEI Jianlin,et al.Correlation analysis of 18F-FDG PET/CT imaging SUVmax and clinical stage and pathological type of non-small cell lung cancer[J].World J Clin Med,2017,11(10):224-225.[邓燕云,滕才钧,韦建林,等.18F-FDG PET/CT显像SUVmax与非小细胞肺癌临床分期及病理分型的相关性分析[J].世界临床医学,2017,11(10):224-225.]
[3]Skoura E,Datseris IE,Platis I,et al.Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non-small-cell lung cancer[J].Clin Lung Cancer,2012(13):181-187.
[4]De Langen AJ,Vincent A,Velasquez LM,et al.Repeatability of 18F-FDG uptake measurements in tumors:A meta analysis[J].J Nuc Med,2012,53(5):701-708.
[5]Lodge MA.Repeatability of standardized uptake value in oncologic 18F-FDG PET[J].J Nucl Med,2017,58(4):116.
[6]Nygrd L,Aznar MC,Fischer BM,et al.Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients[J].Am J Nuc Med & Mole Imaging,2018,8(2):127-136.
[7]Lordick F,Ott K,Krause BJ,et al.PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction:The MUNICON phase II trial[J].Lancet Oncol,2007(8):797-805.
[8]Capirci C,Rampin L,Erba PA,et al.Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy[J].Eur J Nucl Med Mol Imaging,2007(34):1583-1593.
[9]Weber WA,Gatsonis CA,Mozley PD,et al.Repeatability of 18F-FDG PET/CT in advanced non-small cell lung cancer:Prospective assessment in two multicenter trials[J].J Nuc Med,2015(114):147728.
[10]Wahl RL,Jacene H,Kasamon Y,et al.From RECIST to PERCIST:Evolving considerations for PET response criteria in solid tumors[J].J Nucl Med,2009,50(Suppl 1):122S150S.
[11]Kramer GM,Frings V,Hoetjes N,et al.Repeatability of quantitative whole-body 18F-FDG PET/CT uptake measures as function of uptake interval and lesion selection in non-small cell lung cancer patients[J].J Nucl Med,2016,57(9):1343-1349.
[12]Groshar D,Bernstine H,Goldberg N,et al.Reproducibility and repeatability of same-day two sequential FDG PET/MR and PET/CT[J].Cancer Imaging,2017,17(1):11.
[13]Frings V,van Velden FH,Velasquez LM,et al.Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies:A multicenter study[J].Radiology,2014,273(2):539-548.
[14]HU N,WANG YH.Application of 18F-FDG PET/CT metabolic parameters in lung cancer[J].Chinese J Nucl Med Mole Imaging,2018(1):59-63.[胡娜,王云华.18F-FDG PET/CT代谢参数在肺癌中的应用[J].中华核医学与分子影像杂志,2018,38(1):59-63.]
[15]Hatt M,Cheze-Le Rest C,Aboagye EO,et al.Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements[J].J Nuc Med,2010,51(9):1368-1376.
[16]Frings V,de Langen AJ,Smit EF,et al.Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer[J].J Nuc Med,2010,51(12):1870-1877.
[17]XIN Zhonghong,ZHANG Hao.Evaluation of the prognosis of malignant tumors by 18F-FDG PET/CT tumor metabolic load parameters[J].Int J Med Radiol,2018,41(04):459-463.[辛仲宏,张皓.18F-FDG PET/CT肿瘤代谢负荷参数评估恶性肿瘤预后的价值[J].国际医学放射学杂志,2018,41(04):459-463.]
[18]Hristova I,Boellaard R,Vogel W,et al.Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727:A randomized,double-blind,placebo-controlled phase Ⅲ trial[J].Eur J Nucl Med Mol Imaging,2015,42(6):848-857.
[19]Boktor RR,Walker G,Stacey R,et al.Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET[J].J Nucl Med,2013,54(5):677-682.
[20]Kunikowska J,Matyskiel R,Toutounchi S,et al.What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions[J]? Eur J Nucl Med Mol Imaging,2014,41(12):2273-2280.
[21]Paquet N,Albert A,Foidart J,et al.Within-patient variability of 18F-FDG:Standardized uptake values in normal tissues[J].J Nucl Med,2004,45(5):784.
[22]Hofheinz F,Bütof R,Apostolova I,et al.An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET[J].Ejnmmi Res,2016,6(1):19.
[23]Hofheinz F,Apostolova I,Oehme L,et al.Test-retest variability in lesion SUV and lesion SUR in 18F-FDG PET:An analysis of data from two prospective multicenter trials[J].J Nucl Med,2017,58(11):1770-1775.
[24]van den Hoff J,Oehme L,Schramm G,et al.The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG[J].EJNMMI Res,2013,3(1):77.
[25]Hofheinz F,van den Hoff J,Steffen IG,et al.Comparative evaluation of SUV,tumor-to-blood standard uptake ratio (SUR),and dual time point measurements for assessment of the metabolic uptake rate in FDG PET[J].EJNMMI Res,2016(6):1-9.
[26]Shin S,Pak K,Kim IJ,et al.Prognostic value of tumor-to-blood standardized uptake ratio in patients with resectable non-small-cell lung cancer[J].Nucl Med Mol Imaging,2017,51(3):233-239.
[27]YU Peng,TIAN Jiahe.Research progress of 18F-FDG PET image texture analysis[J].Chinese J Med Imaging,2014,22(09):711-713.[于鹏,田嘉禾.18F-FDG PET图像纹理分析的研究进展[J].中国医学影像学杂志,2014,22(09):711-713.]
[28]XU Tianwei.Study on tumor heterogeneity based on texture features of PET images[D].Shandong:Shandong Normal University,2016.[徐天伟.基于PET图像纹理特征的肿瘤异质性研究[D].山东:山东师范大学,2016.]
[29]Tixier F,Hatt M,Rest CCL,et al.Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in F-18-FDG PET[J].J Nuc Med,2012,53(5):693-700.

备注/Memo

备注/Memo:
国家重点基础研究发展计划(编号:2015CB931800);National Natural Science Foundation of China(No.81627901);国家自然科学基金项目(编号:81627901);黑龙江省高校分子影像重点实验室基金资助
更新日期/Last Update: 1900-01-01